Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

WQWenbin QianWLWen Lei

Discussion

Loading...

Member takes

Overview

Analysis reveals that CAR-HEMATOTOX score predicts adverse effects and progression-free survival in B-cell lymphoma patients undergoing CAR-T treatment, implying better patient management.

Key Points

  • High-risk patients experienced significantly greater rates of hematological toxicity, with 100% of them facing grade 3 or higher toxic events.
  • The study included 39 patients with relapsed/refractory B-cell lymphoma treated with 7×19 CAR-T therapy and evaluated using CAR-HEMATOTOX scoring.
  • Patients classified as high-risk exhibited lower overall survival rates compared to low-risk patients, at 15% versus 42% respectively at 24 months.
  • CAR-HEMATOTOX score effectively identifies high-risk patients, which may enable optimization of supportive therapies to manage toxic events.

Cite This Study

Qian et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc16https://doi.org/10.1182/blood-2025-7687
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy2025
  2. 2CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia2025 · 4 citations
  3. 3CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)2025
  4. 4Evaluating the CAR-hematotox score in patients with refractory-relapsed multiple myeloma treated with bispecific T-cell engager therapy2025
  5. 5Cytopenias and infectious complications following CD19-directed CAR-T cell therapy in patients with B-ALL: A single-center retrospective analysis2025